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THE REBOUND PHENOMENON IN ACUTE RHEUMATIC FEVER
1. INCIDENCE AND SIGNIFICANCEt
When anti-inflammatory treatment is reduced or stopped in patients with
acute rheumatic fever, clinical or laboratory evidence of rheumatic activity
sometimes reappears. This phenomenon had occasionally occurred after
salicylate therapy9"8 in the pre-steroid era, but the name "rebound" came
into use only in recent years"' when the incidence of the event was so fre-
quent after steroid treatment that a specific title was given to it.
Studies of the rebound phenomenon are sparse'6' 7'10"
, and have been
performed under two sets of disadvantages. One difficulty has been the
selection of patients and therapy:
1. Thenumber ofpatients has been small,710,1 or chosen from an adult
population."'
'
2. Since the duration of drug therapy in several studies7""'8 was identi-
cal forallpatients, the effects of different lengths of treatment could not be
determined.
3. The post-therapeutic follow-up period was often short so that the
occurrence of late rebounds could not be detected.
A second difficulty has been the identification of the phenomenon:
1. The "rebound" is not uniformly defined, and is described by varying
criteria.
2. Rebounds where the only abnormalities were in laboratory tests,
have not often been distinguished from those which included clinical fea-
tures; in the latter group, cardiac and noncardiac events have not been
separated.
3. The pre-therapeutic clinical status of the patients has seldom been
correlated with the features of the associated rebound.
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4. Bacteriological and immunological techniques have rarely been used
to demonstrate the absence of intercurrent streptococcal infections, in
order to prove that the recurrent inflammation was a post-therapeutic
rebound rather than a new attack of rheumatic fever.
As a result of these inconsistencies, the rheumatic-fever rebound phe-
nomenon has been poorly understood and has received various interpreta-
tions. It has been attributed to (i) polycyclic rheumatic fever ,(ii) with-
drawal of treatment before the natural course of inflammation had subsided,
(iii) relative adrenal insufficiency, or (iv) the accumulated rheumatic in-
flammation whose clinical outlet had been prevented by the preceding sup-
pressive treatment. The relative importance of these four possible causes is
uncertain.
The present survey has studied the incidence and significance of the
rebound phenomenon in the attacks of acute rheumatic fever in 265 children
and adolescents, treated with a variety of agents and followed throughout
the convalescent period and beyond. The results help clarify the nature of
the rebound process and have clinical and conceptual implications for the
natural history and management of rheumatic activity.
CLINICAL MATERIAL AND METHODS OF STUDY
The patients were drawn from 331 consecutive admissions to Irvington House during
the 26-month period beginning 1 July 1956. Of these patients, 44 had not had rheumatic
fever and 22 had illnesses which had been originally labeled rheumatic fever but
which did not fulfill the modified Jones criteria2 for this diagnosis. The remaining 265
patients all had had unequivocal attacks of rheumatic fever and constitute the subjects
of this report.
They were admitted to Irvington House at different phases of the acute rheumatic
attack and in different stages of various kinds of anti-inflammatory therapy. Some
arrived early in the attack while receiving no treatment or full doses of anti-
inflammatory drugs, while others were sent purely for convalescence after all therapy
had been stopped.
The routine management at Irvington House was as follows: Rectal temperature and
"sleeping" pulse rate were measured daily. The uncorrected* (Wintrobe) erythrocyte
sedimentation rate and serum C-reactive protein were tested at weekly intervals for at
least eight weeks after both of these acute phase reactants had become and remained
normal following cessation of anti-inflammatory therapy. All patients received con-
tinuous oral or parenteral prophylaxis** against streptococcal infections. These
*Wintrobe'2 no longer recommends correction of the sedimentation rate for changes
in hematocrit.
** Grateful acknowledgement {or the supply of these agents is given to Lederle
Laboratories (for sulfadiazine), to E. R. Squibb and Sons (for oral penicillin
"pentids"), and to Wyeth and Co. (for repository penicillin, "bicillin").
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infections were sought by bacteriological and serological techniques. Throat cultures
were taken for three consecutive days after admission and repeated thereafter when
clinically indicated. The anti-streptolysin 0 titer was measured on admission and at
monthly intervals until discharge. When there was clinical, bacteriological, or sero-
logical suspicion of streptococcal infections, consecutive sera were simultaneously
tested for anti-streptolysin 0, antistreptokinase, and anti-hyaluronidase titers.'7 Periodic
dental examinations and appropriate local dental therapy helped maintain asepsis of
the teeth and gums and removed dental inflammation as a potential cause10 of fever
and infection.
Since the patients came from many different sources, their initial therapeutic manage-
ment was varied and could not be statistically randomized. After they reached Irvington
House, the subsequent treatment depended on their clinical status and laboratory tests.
When uncontrolled rheumatic activity was present, medication was begun or altered
until the inflammation was suppressed. When the disease was under therapeutic control,
the dosage of the anti-inflammatory agent was gradually lowered and discontinued after
varying lengths of time, depending on the nature and duration of previous treatment
and the condition of the patient.
The details of each patient's clinical and laboratory data at the referring institutions
were added to the Irvington House records to obtain a chronology of the complete
course of each rheumatic attack, from onset to the end of convalescence. These data
were then searched for evidence of a rheumatic rebound. A rebound was defined as the
reappearance of clinical or laboratory features of rheumatic activity after these mani-
festations had originally subsided, in the absence of an intercurrent Group A strepto-
coccal infection. If abnormal vital signs and acute phase reactant values had not
previously become normal, neither their reappearance nor the occurrence of clinical
abnormalities was considered a rebound. This definition thus excluded patients in
whom the original treatment may have been inadequately suppressive and it also
permitted consideration of the rebound in situations where no suppressive treatment
was used.
In a patient with recent unequivocal rheumatic fever and without an intercurrent
streptococcal infection, the reappearance of rheumatic activity was defined according
to the following criteria of abnormality:
Laboratory criteria
1. An uncorrected (Wintrobe) erythrocyte sedimentation rate of greater than
20 mm./hr.
2. Serum C-reactive protein of trace or more.
Clinical criteria
1. A temperature of greater than 100.40 F., rectally, occurring for three consecutive
days (unless treatment intervened).
2. "Sleeping" pulse rate higher than 90 per minute, not associated with fever,
occurring for three consecutive days (unless treatment intervened).
3. Recurrence of significant joint symptoms or signs.
4. The appearance of diastolic murmurs or of pericardial friction rubs, when these
were unequivocal and were clearly new developments.
5. The development of congestive heart failure.
6. The appearance of nodules or erythema marginatum.
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The pulse rate measurements were taken while the patients were asleep, to ensure that
tachycardia was not due to psychic stimulation. The occurrence or reappearance of
chorea was not listed as a specific manifestation of rheumatic activity, because the
precise time of onset or cessation of choreic movements is difficult to determine, and
because they often occur as a late manifestation of the same initial attack."'19 Prolonga-
tion of the P-R interval was omitted from these parameters of rheumatic activity
because of difficulties in its accurate graphic measurement," uncertainties about the
range of normality permitted at different cardiac rates,' the absence of correlations
between its prolongation and other features of carditis,' and finally, because it sometimes
remains permanently prolonged without relation to the rheumatic course.'
Using the above criteria for rheumatic activity, the following classification of
rebounds could be made:
1. No rebound.
2. Slight "laboratory rebound": CRP trace and/or ESR 21-30 mm./hr.
3. Significant "laboratory rebound": CRP 1+ or higher and/or ESR of over
30 mm./hr.
4. Slight "clinical rebound": laboratory indications or rebound, together with fever.
5. Significant "clinical rebound": laboratory indications of rebound, with or without
fever, together with any of the other clinical criteria cited above.
Clinical features had to be associated with laboratory abnormalities in order to be
classified as a "clinical rebound." This specification avoided difficulties in evaluating
the cause of minor arthralgias and other subjective complaints, and in analyzing non-
specific changes in the intensity of established auscultatory phenomena. Untreated fever
or nocturnal tachycardia had to be present for three days before the assumption that
they were part of a clinical rebound. This specification eliminated the sporadic,
isolated rises in temperature and pulse which occur so frequently in hospitalized
patients. Clinical or laboratory abnormalities were attributed to a rebound only when
there were no alternative likely causes-such as nonspecific respiratory illnesses,
transient reactions to injections of benzathine penicillin,' etc.
For the analysis of anti-inflammatory therapy the patients were divided into four
groups:
1. No treatment. These patients had received no anti-inflammatory therapy or had
been given only sporadic, isolated doses.
2. Salicylate treatment. These patients had received a definite course of some
salicylate preparation, generally aspirin.
3. Steroid treatment. These patients had received steroids exclusively, the most
commonly used agents being cortisone, prednisone, and/or ACTH.
4. Combined treatment. These patients had received salicylates and steroids together,
the combinations having been given in many different forms. All patients in this
group had received at least ten days of salicylate and at least five days of steroid
therapy. (Patients on steroids who had previously received aspirin for less than
ten days were classified with those who received steroids alone.) In 23 patients
the two drugs were started together, the administration of salicylate continuing
after steroid was stopped. In 13 patients steroid was added after salicylate was
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started, and was continued beyond the cessation of salicylate therapy. The
remaining 13 patients in the "combined" group received the two drugs sequentially
or concomitantly in a variety of patterns. A rebound was associated with "com-
bined" therapy only if the patient had previously received both types of treatment.
For classification of the intial clinical status, the patients were divided as follows:
Those with "no valvular involvement" had had only arthritis or chorea but lacked the
diastolic murmurs or significant apical systolic murmurs which characterized those
with "valvular involvement."2'5 The distinction between physiological and pathological
apical systolic murmurs was made according to previously described criteria of
loudness, length, and location. " In the group with valvular involvement, patients with
significant heart enlargement (i.e., at least one chamber 2+ enlarged) were separated
from those with no or slight cardiomegaly.
TABLE 1. TYPES OF REBOUNDS IN RELATION TO PRECEDING THERAPY
(THE FIGURES SHOW THE NUMBER OF PATIENTS IN EACH CATEGORY)
Type of rebound
Laboratory Clinical
Type of None Slight Significant Slight Significant
therapy (1) (2) (3) (4) (5) Total
Salicylate 52 15 29 1 9 106
Steroid 25 14 12 3 23 77
Combined 21 8 6 4 9 48
None 22 6 6 0 0 34
Total 120 43 53 8 41 265
RESULTS
Types ofrebound and relation to previous treatment
The following features may be noted from Table 1:
1. A rebound occurred in more than half the patients (145/265). In the
individual treatment groups, a rebound occurred in the following percent-
ages: salicylates, 51 per cent (54/106); steroid, 68 per cent (52/77);
combined, 56 per cent (27/48) ; and no treatment, 35 per cent (12/34).
2. There were 43 slight and 53 significant laboratory rebounds. They
occurred even in patients who had received no anti-inflammatory therapy,
appearing in more than one third (12/34) of the "untreated" group.
3. Of the 12 "untreated" patients with laboratory rebounds, 5 had no
heart disease and 7 had valvular involvement without significant cardio-
megaly. These rebounds occurred: during early ambulation after strict
bedrest (in 4); in the first two weeks after transfer to the ambulatory unit
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(in 5); beyond two weeks after transfer to the ambulatory unit (in 3).
Since the progression to ambulation was often made as soon as the acute
phase reactants reached normal values, it is to be expected that some eleva-
tions in these values would occur spontaneously while the patients were
ambulatory. These data therefore do not permit the conclusion that the
laboratory rebounds in this group necessarily were due to the ambulation.
4. There were 8 slight and 41 significant clinical rebounds. In patients
who received suppressive treatment, clinical rebounds occurred with the
following frequency: salicylates, 9 per cent (10/106); steroid, 34 per cent
(26/77); and combined treatment, 27 per cent (13/48). No clinical
rebounds occurred in the untreated patients.
TABLE 2. TYPE OF TREATMENT IN RELATION TO INITIAL CLINICAL STATUS
(THE FIGURES SHOW THE NUMBER OF PATIENTS IN EACH CATEGORY)
Type of treatment
Clinical status None Salicylate Steroids Combined Total
No valvular involvement 19 48 28 19 114
Valvular involvement without sig-
nificant heart enlargement 14 49 33 19 115
Valvular involvement with signifi-
cant heart enlargement 1 9 16 10 36
Total 34 106 77 48 265
These data indicate that a laboratory or clinical rebound (as herein
defined) is a common event in acute rheumatic fever, occurring in more
than half of the patients in this survey. Laboratory rebounds occurred even
in patients who received no anti-inflammatory therapy; clinical rebounds
occurred only in patients who received anti-inflammatory therapy and were
significantly more frequent in those whose treatment included steroids than
in those who received salicylate alone, (X2 = 13.4; p < 0.01).
Types of treatment and relation to clinical status of patients (Table 2)
In patients with little or no cardiac damage, salicylates alone were used
as frequently as steroids and combined therapy. In patients with significant
cardiomegaly, the number who received steroid and combined treatment was
almost three times as great as those who were given aspirin alone. The
greater use of steroids in the latter group of patients may be due to two fea-
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tures. First, many physicians continue to prefer steroids for acutely ill
patients with significant heart disease even when no cardiac failure is pres-
ent. Secondly, when it was believed that carditis was not adequately con-
trolled by salicylates alone, steroids were added to the treatment. In this
situation the patient's therapy would be classified in the steroid or combined
group.
Types of rebound and relation to clinical status of patients (Table 3*)
Of the patients with no valvular evidence of heart disease, 54 per cent
(62/114) had no rebound, while 12 per cent had a clinical rebound. Of
TABLE 3. TYPES OF REBOUNDS IN RELATION TO INITIAL CLINICAL
STATUS OF PATIENTS
(THE FIGURES SHOW THE NUMBER OF PATIENTS IN EACH CATEGORY)
No Laboratory Clinical
Clinical status rebound rebound rebound Total
No valvular involvement 62 38 14 114
Valvular involvement without significant
heart enlargement 53 43 19 115
Valvular involvement with significant
heart enlargement 5 15 16 36
-Total 120 96 49 265
those who had valvular heart disease without significant cardiac enlarge-
ment, 46 per cent (53/115) had no rebound, 17 per cent had a clinical
rebound. Of the patients with significant cardiac enlargement, only 14 per
cent (5/36) were free of rebound, while clinical rebounds occurred in 44
per cent (16/36). These data are statistically significant (X2 - 17.3, p
<0.01) and suggest that an increase in the severity of heart disease pre-
disposes to an increased incidence of clinical rebound. However, as Table 2
indicates, steroid treatment was used more often in patients with severe
heart disease, and the higher incidence of clinical rebounds in this group
might possibly be related to the therapy rather than to the cardiac status.
This possibility is explored in Table 4, below.
* For this and subsequent tables, the designation "laboratory" and "clinical" rebounds
combines the "slight" and "significant" sub-groups of each category.
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Types of rebounds and relation to clinical status and preceding treatment
(Table 4)
In patients with no valvular involvement, a clinical rebound occurred in
6per cent ofthose treated with salicylate, in 18 per cent of the steroid group,
and in 32 per cent of those who received combined therapy. For these
patients, the lower incidence of clinical rebounds after salicylates as com-
pared to steroids and combined therapy is statistically significant (X2
4.75, p <0.05). In patients with evidence of valvular disease but without
significant cardiomegaly, a clinical rebound occurred in the treatment groups
TABLE 4. INCIDENCE OF CLINICAL REBOUNDS IN RELATION TO PRECEDING
TREATMENT AND INITIAL CLINICAL STATUS
Initial clinical Number weith
status of Therapeutic Number of clinical
patients agent patients rebounds Percentage
No valvular involvement None 19 0 0%
Salicylate 50 3 6%
Steroids 28 5 18%
Combined 19 6 32%
Valvular involvement None 14 0 0%
without significant Salicylate 48 5 10%
heart enlargement Steroids 33 12 36%
Combined 19 2 11%
Valvular involvement None 1 0 0%
with significant Salicylate 8 2 25%
heart enlargement Steroids 16 9 56%
Combined 10 5 50%o
as follows: salicylates, 10 per cent; steroids, 36 per cent; combined therapy,
11 per cent. For these patients the incidence of clinical rebounds after
salicylates is significantly lower than that after steroids alone (X2 - 7.94;
p<0.01) and somewhat less significantly lower (X2 = 3.41; p <0.10) when
compared against the total of steroid and combined therapy. In patients who
had significant cardiac enlargement, clinical rebounds occurred in the treat-
ment groups as follows: salicylates, 25 per cent; steroids, 56 per cent; com-
bined, 50 per cent. For these patients, the post-salicylate clinical rebound
percentages are not significantly lower thantheothers (X2 - 1.05; p <0.3).
The partial superiority of salicylates suggested by these results must be
viewed with reservation. In the initial selection of treatment, patients who
were more severely ill were often given steroids immediately. Patients
2"
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treated with salicylates who failed to show a suitable clinical response usually
had steroids added to the therapy. Patients with "chronic" or unusually
prolonged rheumatic activity, whose acute phase reactants never reached
normal values under salicylate therapy, either received additional steroid
treatment or did not qualify for classification in the "rebound" group accord-
ing to the criteria of the present study. Thus the patients of this survey who
TABLE 5. INCIDENCE OF CLINICAL REBOUNDS IN RELATION TO INITIAL
CARDLAC STATUS AND LENGTH OF ANTI-INFLAMMATORY TREATMENT
(In each instance, the denominator gives the total number of patients in
each group, and the numerator gives the number who had clinical rebounds)
Initial cardiac status,
No valvular involvement
Valvular involvement
Salicylate * without significant
heart enlargement
Valvular involvement
with significant
heart enlargement
Total
Steroid
No valvular involvement
Valvular involvement
without significant
heart enlargement
Valvular involvement
with significant
heart enlargement
Total
0-4
1/12
Weeks of treatment
4-8 8-12 over 12
2/26 0/10 0/2
Total
3/50
3/11 2/24 0/10 0/3 5/48
1/2 1/4 0/1 0/1 2/8
5/25 5/24 0/21 0/6 10/106
1/8 2/16 0/1 2/3 5/28
0/2 3/16 3/8 6/7 12/33
0/0 2/5 3/7 4/4 9/16
1/10 7/37 6/16 1Z/14 26/77
received only salicylates were more likely to be those who had a relatively
benign clinical course. In those whose therapeutic response to salicylate was
not ideal, steroids were often added to the treatment and any subsequent
rebounds were then attributed to "combined" therapy, rather than to
salicylates alone.
Types of rebound and relation to duration of preceding treatment (Table 5)
The after-effects of therapy may be influenced by its dosage and duration.
In considering the relation of these variables to subsequent rebounds, only
the salicylate and steroid groups could be analyzed because "combined"
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therapy had been given in too many different ways to permit detailed classi-
fication. The occurrence of rebounds was tabulated in both the steroid and
salicylate groups with regard to total dosage of the agent (sum of the daily
doses) and the total duration of treatment. In addition, treatment in
salicylate patients was classified, using body weight, into units of total dos-
age per pound. No striking correlations emerged with either agent, from a
consideration either of total dosage or of total dosage per pound. The data
on duration of treatment seemed to be more significant and are listed in
Table 5. In patients who received salicyates, clinical rebounds occurred,
TABLE 6. INCIDENCE OF CLINICAL REBOUNDS IN RELATION TO
AGE AND SEX OF PATIENTS AND TREATMENT USED
(In each instance, the denominator gives the total number of patients in each
group, and the numerator gives the number of those who had clinical rebounds)
Treatment used
Age (years) None Salicylate Steroid Combined Total
4-9 0/1 3/20 6/15 3/7 12/43 (28t%)
Boys 10-14 0/12 3/41 10/26 7/19 20/98 (20%)
>14 0/2 1/11 0/3 2/4 3/20 (15%)
Total 0/15 7/72 16/44 12/30 35/161(22%)
4-9 0/9 0/13 7/16 0/9 7/47 (15%)
Girls 10-14 0/8 3/16 3/14 1/9 7/47 (15%)
>14 0/2 0/5 0/3 ... 0/10 (0%)
Total 0/19 3/34 10/33 1/18 14/104(13%)
irrespective of cardiac status, only in those treated less than 8 weeks. In
patients who received steroids, the incidence of clinical rebounds increased
as the duration of treatment increased: they appeared in 10 per cent (1/10)
of those treated for 0-4 weeks, in 19 per cent (7/37) of the 4-8 week group,
and 38 per cent (6/16) of the 8-12 week group, and in 86 per cent (12/14)
of those treated for more than 12 weeks. This relationship is statistically
significant (X2 - 15.7, p <0.01). This table also shows that post-steroid
clinical rebounds (as noted in Table 4) were increasingly likely as the
severity of heart disease was increased.
These results indicate that steroid treatment, given for more than 8 weeks,
was associated with clinical rebounds in more than half of the patients, par-
ticularly in those with more severe cardiac damage. Salicylate treatment
maintained for longer than 8 weeks appeared to prevent clinical rebounds,
2"
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regardless of cardiac status, but the present survey included only 2 patients
with significant cardiomegaly who received salicylate alone for over 8 weeks.
Clinical rebounds in patients in this category have been noted previously at
Irvington House and elsewhere, and the present data do not imply that
rebounds will always be prevented by long-term salicylate treatment.
Relation of clinical rebounds to age and sex (Table 6)
Clinical rebounds occurred in 35 (22 per cent) of the 161 boys in this
series, and in 14 (13 per cent) of the 104 girls. Despite the tendency of
steroids to produce striae, acne, and other cutaneous changes, hormonal
TABLE 7. INTERVAL BETWEEN CESSATION OF TREATMENT AND OCCURmNCE
OF REBOUND
(THE FIGURES SHOW THE NUMBER OF PATIENTS IN EACH CATEGORY)
. - ~~~~~~~~~~~Type of rebound Timne of occurrence of rebound
after cessation of treatment Laboratory Clinical
During tapering to 1st week after 26 39
1-2 weeks 14 4
2-4 weeks 23 3
4-8 weeks 20 3
Beyond 8 weeks 13 0
therapy was used in 49 per cent of the girls (51/105) compared to 46 per
cent (74/161) of the boys. The present data do not confirm a previous
observation'0 that clinical rebounds were most prevalent in teen-age girls.
At all three age groupings in the present survey, clinical rebounds occurred
more often in boys than in girls, and the likelihood of their appearance was
less as the boys grew older. In the girls the incidence was the same in the
age group 4-9 as in the age group 10-14, and no clinical rebounds occurred
ingirls over 14 years ofage. None of these age-sex differences has statistical
significance, however.
Relation of rebounds to penicillin treatment
Recently, it has been suggested" that large doses of penicillin, given after
the onset of the rheumatic attack, may reduce the residual cardiac damage.
This hypothesis has not been tested in the present study. However, the
relationship of penicillin treatment to subsequent clinical rebounds could be
considered. Of 130 patients who received only sporadic penicillin treatment
or none, clinical rebounds occurred in 26 (20 per cent). Of those who
definitely received a streptococcal-eradicating course of penicillin, clinical
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rebounds occurred in 11 per cent (8/74). This difference in the two groups
is not significant, however, since X2 = 2.25, with p >0.1. It should be noted
that Mortimer et al.'4 found no difference in frequency of rebounds in the
treated and untreated groups in their study of massive penicillin therapy.
Time interval between end of treatment and occurrence of rebounds
(Table 7)
In patients with laboratory rebounds, the abnormal acute phase reactants
appeared sporadically following their original return to normal levels.
Although more laboratory rebounds occurred during the first week than at
any other time after cessation of therapy, they also occurred in appreciable
frequency at subsequent periods. Of the laboratory rebounds, 86 per cent
had occurred by the end of eight weeks while 14 per cent took place beyond
eight weeks. In contrast, most (80 per cent; 39/49) of the clinical rebounds
occurred while therapy was being tapered or during the first week after it
was stopped. Noclinical rebound occurred eight weeks or more after therapy
was stopped. Thus, patients who did not have a clinical rebound within a
week or two after cessation of therapy were likely to complete their course
without having one, and would not have one after eight weeks. On the other
hand, elevations of acute phase reactants (a laboratory rebound) could
occur anytime within the first two post-therapeutic months and appeared
even later in 14 per cent of patients.
Features and sequelae of the rebounds
Figures 1 and 2 illustrate the sequence of events in two patients with
clinical rebounds. It is of interest that laboratory rebounds subsided spon-
taneously in all cases and had no subsequent clinical effects. The details of
the events, management, and sequelae of clinical rebounds are described
separately.'6 In the 49 clinical rebounds of the present group, new cardiac
damage did not occur in 14 patients who initially had no valvular involve-
ment. Of the 35 patients who originally had carditis, 10 developed new
cardiac events and in 2, the damage seemed permanent. The incidence of
new cardiac damage in the 35 clinical rebounds of this group was related to
previous treatment as follows: salicylate, 4 in 7; steroids, 5 in 21; combined,
1 in 7. These numbers are too small for comparative statistical significance.
It should be noted that the incidence of clinical rebounds and of individual
events within them is somewhat less in the present series than in those
reported previously. Some of these differences are probably due to the cri-
teria used to define the rebound, and the demand in the present study that
values for acute phase reactants had to have achieved normal limits before
the reappearance of abnormal features could be considered a true rebound.
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DISCUSSION
A disadvantage of the present analysis is that, like most other studies of
the rebound phenomenon, it is retrospective; the therapeutic agents were
not chosen randomly and were not always maintained according to a pre-
5 5 15 25 5 15
ar. April May
25 5 15
June
25 5 15 25 5 15
July Aug.
FIG. 1. Two clinical rebounds with first attack of rheumatic fever in an 11-year-old
boy. The initial arthritis and fever had subsided before admission to hospital. Combined
therapy was begun because of a systolic murmur, loudest along the left sternal border,
and positive acute phase reactants. After all abnormalities subsided, fever and arthritis
returned when cortisone was stopped and reappeared later when aspirin was stopped.
The systolic murmur was finally thought to be physiological, and no other suggestions
of carditis were found. Patient has remained free of heart disease.
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FIG. 2. Ne-w cardiac features with a clinical rebound in a 14-year-old girl. This first
attack of rheumatic fever began with polyarthritis and a significant apical systolic
murmur. All abnormalities subsided on salicylate therapy, which was stopped after
four weeks. Within the next two weeks the patient developed fever, arthritis, and a
basal blowing diastolic murmur, together with an elevated ESR and CRP. All features
of the rebound subsided spontaneously in the next few weeks except for the diastolic
murmur. Hemodynamic changes of aortic regurgitation did not occur, however, and
the murmur disappeared in the next two years.
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arranged plan. This same circumstance in the current survey, however, is
advantageous because it provides the opportunity to compare the results of
various therapeutic agents and the influence of different durations of treat-
ment. These comparisons could not be made in studies where salicylates
and/or steroids were given to all patients for the same length of time and
where "combined" treatment had not been used. The present work has sev-
eral other advantages: the patients were in the younger age group where
rheumatic fever predominates, their number is several times greater than in
any previous reports, an untreated group was available for study, and the
rebounds were related to the initial clinical status of the patients. The
division of patients into three clinical categories has helped to minimize the
effects of nonrandom allocation of therapeutic agents and has enabled the
recognition of direct correlations between the cardiac status and the occur-
rence and types of clinical rebounds.
The results show that rebounds are a common event in acute rheumatic
fever; they appear in two ways, each with different consequences. The lab-
oratory rebound consists only of abnormalities in acute phase reactants of
the blood. It subsides in all patients without additional therapy and it appar-
ently does not affect the patients' clinical status. By contrast, the clinical
rebound is more to be feared because of its acute, and potentially permanent,
cardiac effects. Although clinical rebounds did not bring carditis to patients
who did not have it initially, they did produce significant new cardiac mani-
festations in some of those who had previously shown evidence of valvular
involvement. The laboratory rebounds were unrelated to clinical status and
preceding therapy; they could be found even in untreated patients. The
clinical rebounds were more frequent with increasing severity of heart dis-
ease, and occurred only in patients who had received anti-inflammatory
therapy; they were particularly common after treatment with steroids.
The implications of these data can be applied to a number of basic and
clinical problems in rheumatic fever. Some of these will be considered sep-
arately.'6 The remainder of the discussion here will be devoted to possible
mechanisms of the rebound phenomenon.
The clinical rebound patterns observed in this survey cannot be well
explained by any of the three possible causes to which this phenomenon is
usually attributed. Polycyclic rheumatic fever' is unlikely because the inci-
dence of rebounds is farhigher than the natural occurrence of multiple rheu-
maticcycles andbecausethe rebounds occur too close to the time of reduction
or cessation of therapy. The persistence of rheumatic activity due to pre-
mature withdrawal of treatment6 does not seem a valid explanation because
so many rebounds occur after extremely long therapeutic courses. Relative
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adrenalinsufficiency' does not account for the rebounds which follow salicy-
late treatment, and hypoadrenalism has seldom been demonstrable in
rebounds after steroid treatment.' Moreover, none of these mechanisms
would account for the increased incidence of clinical rebounds as the severity
of cardiac damage increases.
An attractive explanation which fits the observed data is provided by a
new hypothesis, which may conveniently be called "suppressed inflamma-
tion." This theory assumes that the average attack of rheumatic fever cre-
ates a fixed amount of inflammation which must be dissipated. The amount
of inflammation will differ in different patients. Its total quantity will deter-
mine the severity of the clinical features. The rapidity with which it appears
will determine the peak of its intensity and the rapidity with which it dissi-
pates will determine the duration of the attack. Anti-inflammatory therapy
will suppress the appearance and dissipation of the inflammation. The sup-
pression can be total or partial, depending on the amount of inflammation
and the therapy employed.
If the suppression is total, as with full doses of steroids, the inflammation
remains dormant and accumulates until the therapy is reduced or stopped.
At that time, the amount of residual inflammation and the rapidity of its
appearance will determine whether the resultant flare-up of rheumatic activ-
ity is more or less severe than the original attack. Longer periods of totally
suppressive therapy will result in greater quantities of residual inflammation
and hence greater likelihood ofpost-therapeutic clinical rebounds.
If the suppression is partial, as with salicylates, some inflammation can
continue to dissipate during the period of treatment although the amount of
inflammation which appears may notbe great enough to create clinical symp-
toms. In this situation, longer durations of therapy would be desirable since
less residual inflammation is likely to remain when the therapy is stopped.
Figure 3 (A-F) shows hypothetical clinical situations to illustrate the
data and the theory derived from them. The course of rheumatic fever in a
typical untreated patient is shown in A. The inflammation first rises to the
level of clinical abnormalities, then drops to the level of only laboratory
abnormalities and finally reaches normal levels. Drawing B shows how this
course would be influenced by along period of steroid treatment. The dotted
line shows the natural course of the untreated disease, and the solid line
shows the effect of the therapy. The steroids suppress inflammation
promptly and profoundly. The undispersed inflammation is shown in the
dotted area. When the steroids are stopped, this inflammation erupts and a
clinical rebound occurs. A long course of steroid therapy will not always be
followed by a clinical rebound, because the original amount of inflammation
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may have been small, or because some dissipation of inflammation may
occur during the long "tapering" period at gradually lowered dosage. Dur-
ing the latter interval, incomplete suppression of inflammation may allow
enough sub-clinical dispersion so that the cessation of treatment will be fol-
lowed by a mild rebound or none. Figure C shows how the course of rheu-
matic activity is influenced by steroid treatment of shorter duration. During
the period of total suppression, less inflammation accumulates so that the
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FIG. 3. Schematic representation of the course of rheumatic activity as affected by
different therapeutic techniques. In each case, the solid black line shows the actual
course under treatment and the dotted line shows the comparative course in the
untreated patient. The heavily shaded area denotes active, overt rheumatic inflammation
and the lightly shaded area shows suppressed rheumatic inflammation which later may
become active. Drawing A shows the course in an untreated patient and the treatments
in B-F are further described in the text.
subsequent rebound is milder. Figure D shows the effect of the less potent
salicylates. These can only suppress inflammation partially to the level of
laboratory abnormalities. This may not achieve ideal results in tests of acute
phase reactants, but it allows the expression of considerable amounts of
inflammation at a subclinical level. If the salicylate is continued for a long
time, enough inflammation may dissipate during the treatment so that the
post-therapeutic remainder is small enough to create little or no rebound.
With a shorter course of salicylate, as in E, the residual inflammation
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resumes its appearance at a higher level of disease activity, so that the
rebounds may reach clinical levels of severity.
These observations will explain why an appropriate form of combined
therapy may reduce the severity of clinical rebounds. With steroid treat-
ment the suppressed inflammation accumulates as shown in the dotted area
of F. During this period, the suppressant effect of salicylates appears super-
fluous. When the steroids are lowered and stopped, however, the dispersion
of inflammation resumes. The presence of salicylates at this time will not
prevent the flare-up from occurring but will help regulate its severity as may
be seen in comparison with Figure B.
Theabove conjectures obviously do notaccountforallaspects ofrheumatic
activity, but appear to offer a satisfactory explanation for most of the
observed clinical rebound phenomena.
SUMMARY
The rebound phenomenon has been studied in265 children and adolescents
consecutively admitted to Irvington House during the acute or convalescent
phases of unequivocal attacks of rheumatic fever. In each patient the analy-
sis included a sustained chronological account of the illness from its onset to
the end of convalescence. The patients were classified according to their
initial cardiac status and the anti-inflammatory treatment which had been
given. The rebound was defined as the reappearance, after initial subsi-
dence, of clinical and/or laboratory manifestations of rheumatic activity, in
the absence of an intervening streptococcal infection.
Laboratory rebounds were defined as the recurrence of abnormal values
only in the erythrocyte sedimentation rate or serum C-reactive protein.
They appeared in 96 patients and all subsided spontaneously without any
evident adverse clinical effects. Their incidence did not seem related to the
clinical status or to the nature of the preceding treatment and they also
occurred spontaneously in patients who received no suppressive treatment.
In treated patients, they appeared at varying intervals after therapy was
stopped and 14 per cent occurred later than 8 weeks.
A clinical rebound, manifested by fever and/or joint pains and/or new
cardiac signs, together with laboratory abnormalities, occurred in 49
patients. In 39, it appeared while treatment was being reduced or during
the first post-therapy week. These rebounds did not bring clinical evidence
of heart disease to patients who were initially free of it. New cardiac dam-
age, however, developed in 10 and persisted in 2 of the 35 clinical rebounds
in patients who initially had valvular involvement. A clinical rebound
occurred more frequently in patients who had valvular damage than in those
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who did not, and was particularly common in those with significant cardiac
enlargement. There were no clinical rebounds in patients who received no
anti-inflammatory therapy. In patients who received suppressive therapy,
clinical rebounds were more prevalent in those given steroids or combined
steroid-salicylate treatment than in those treated with salicylate alone. In
the salicylate-treated group, the incidence of clinical rebounds was unrelated
to cardiac status and they occurred exclusively in those patients who
received therapy for less than 8 weeks. In the group treated with steroids
the incidence of clinical rebounds increased markedly as the duration of
treatment increased and was particularly high in patients with substantial
initial cardiac damage. "Combined" therapy was associated with approxi-
mately the same incidence of clinical rebounds as steroid treatment alone,
but the rebounds seemed less severe.
Of the various hypotheses which have been advanced for the pathogenesis
of most clinical rebound phenomena, the most satisfactory explanation
appears to be that suppressive medication prevents the dispersion of rheu-
matic inflammation and that the accumulated residual inflammation then
appears in the form of a rebound when the suppression is reduced or stopped.
The severity of the rebound will depend upon how much inflammation was
present initially, how much of it was suppressed by the therapy, and how
much remains afterwards.
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